A phase II study of dasatinib in patients with chemosensitive relapsed small cell lung cancer (Cancer and Leukemia Group B 30602).
about
Small cell lung cancer (SCLC): no treatment advances in recent yearsTargeting Src family kinases in anti-cancer therapies: turning promise into triumphA phase II trial of the Src-kinase inhibitor saracatinib after four cycles of chemotherapy for patients with extensive stage small cell lung cancer: NCCTG trial N-0621.Novel dual Src/Abl inhibitors for hematologic and solid malignancies.An update on dual Src/Abl inhibitors.Phase II study of dasatinib in patients with advanced non-small-cell lung cancerDasatinib in previously treated metastatic colorectal cancer: a phase II trial of the University of Chicago Phase II Consortium.Current and emerging pharmacotherapies for the treatment of relapsed small cell lung cancer.Rapamycin Enhances the Anti-Cancer Effect of Dasatinib by Suppressing Src/PI3K/mTOR Pathway in NSCLC Cells.Immunotherapy treatments for small-cell lung cancer: past, present and future.The development of targeted therapy in small cell lung cancer.Treatment-related toxicities in a phase II trial of dasatinib in patients with squamous cell carcinoma of the lungLiposomal bortezomib is active against chronic myeloid leukemia by disrupting the Sp1-BCR/ABL axis.Research progress in the treatment of small cell lung cancer.Rash with the multitargeted kinase inhibitors nilotinib and dasatinib: meta-analysis and clinical characterization.Advances in pharmacotherapy of small cell lung cancer.Src and STAT3 inhibitors synergize to promote tumor inhibition in renal cell carcinoma.The 2016 John J. Abel Award Lecture: Targeting the Mechanical Microenvironment in Cancer.A regulatory circuit composed of DNA methyltransferases and receptor tyrosine kinases controls lung cancer cell aggressiveness.Second-line treatments of small-cell lung cancers.Phase II Study of Dasatinib in Previously Treated Patients with Advanced Non-Small Cell Lung Cancer.Determination of dasatinib in the tablet dosage form by ultra high performance liquid chromatography, capillary zone electrophoresis, and sequential injection analysis.
P2860
Q26767020-64DC53D7-F2E7-4023-8480-1640183C143EQ27025646-B8325A2A-E03D-4318-9C5E-C0179B3245C6Q33416075-5E4E0716-3414-4BD3-9674-3450C90DCC9CQ34121339-C5FECFD7-DF06-4E2D-BEA8-8B3B97CFE42FQ34270677-D80FF56E-A9DA-4B16-8607-13CA6760F8F5Q34281221-6C6BA856-975B-4D6A-AFCB-989D4CC7B0FBQ35050239-677BEEA8-0CF8-40D6-AAAC-B74E2241A1B6Q35155464-B530672E-8E83-4149-ABBB-0A08EFC9A71EQ35659675-887B12BD-0FF5-400F-A466-678862904D3AQ35904003-C9BE0B29-8A58-4AA2-A332-E9EDC5BB29C6Q37127932-9DC59367-4C84-4AFD-A18D-17D67EA35AABQ37241709-FC9B91A8-ECDE-4105-8D16-912FD7235D24Q37392719-A7092E4F-5AD0-488D-90E6-CDFB0F826B36Q37604301-EAA773AB-DE88-4C9B-9448-270EC1C24921Q38067464-9F2F3B9D-E4DC-4296-B327-49E89E47F2F3Q38254295-B0C6178B-1245-4098-826F-D66E55A73DD3Q38815335-73335847-7ADC-4F9A-9E57-BBDA7F6AB4FBQ38981265-F3820AF6-BE16-4701-A863-A5F4C0C75E23Q40059049-DA07084F-3500-4BBD-BAF6-1FD7668D8792Q47789861-57A20CF7-1DB8-4DC9-8589-C78EFA826799Q48022638-FFB9F5B1-FB1F-4B09-82A0-F70AB0508873Q50195493-7962ABA7-8CA6-4330-9AD2-C0DE18D3785A
P2860
A phase II study of dasatinib in patients with chemosensitive relapsed small cell lung cancer (Cancer and Leukemia Group B 30602).
description
2010 nî lūn-bûn
@nan
2010 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի մարտին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
A phase II study of dasatinib ...... r and Leukemia Group B 30602).
@ast
A phase II study of dasatinib ...... r and Leukemia Group B 30602).
@en
type
label
A phase II study of dasatinib ...... r and Leukemia Group B 30602).
@ast
A phase II study of dasatinib ...... r and Leukemia Group B 30602).
@en
prefLabel
A phase II study of dasatinib ...... r and Leukemia Group B 30602).
@ast
A phase II study of dasatinib ...... r and Leukemia Group B 30602).
@en
P2093
P2860
P1476
A phase II study of dasatinib ...... r and Leukemia Group B 30602).
@en
P2093
Antonius A Miller
Cancer and Leukemia Group B (CALGB)
Gregory A Otterson
Herbert Pang
Lydia Hodgson
Michael J Kelley
Nithya Ramnath
Robert A Kratzke
P2860
P304
P356
10.1097/JTO.0B013E3181CEE36E
P577
2010-03-01T00:00:00Z